MOUNTAIN VIEW, Calif., May 5, 2011 /PRNewswire/ —
Xlumena, Inc., a privately-held provider of innovative technology
for the interventional endoscopist and endoscopic surgeon,
announced today that it has received CE Mark approval for its
revolutionary AXIOS™ Stent and Delivery System (AXIOS). The
AXIOS is the first stent designed for endoscopic ultrasound-guided
translumenal therapy and is indicated for drainage of pancreatic
pseudocysts. Having achieved this important milestone, Xlumena will
begin a targeted commercial launch of the AXIOS in select European
markets.
“The AXIOS Stent opens up a frontier of new treatments in and
around the gastrointestinal tract. Not only does the AXIOS
Stent create a large, secure drainage pathway – equivalent to
a surgical anastomosis – it also provides an access port to
pass the endoscope into the duct or lumen cavity for targeted
therapy. This technology has the potential to expand the role
of endoscopy in treating a variety of disorders of the pancreatic
and biliary system,” stated Kenneth Binmoeller, MD, Director of
Interventional Endoscopy Services at California Pacific Medical
Center in San Francisco, California.
Unlike tubular stents used for bile and pancreatic duct
drainage, the AXIOS Stent is designed to hold two lumens in
apposition for translumenal drainage. The bilateral anchors
of the AXIOS Stent prevent movement and migration and the
large-diameter Stent lumen ensures drainage. The AXIOS
is fully covered to prevent leakage across the stent and tissue
ingrowth and facilitate removal. The AXIOS Stent comes
pre-loaded in a specially-designed Delivery System and is easily
deployed by a single operator.
“AXIOS leverages the expertise and vision of the interventional
endoscopy community. It represents a new frontier in endoscopic
therapy that uses ultrasound to guide intervention outside of the
gastrointestinal tract. This avoids m
‘/>”/>
